AOA Dx Named Winner of TEAMFund Health's 2026 Global Health Innovation Award
LongeVC portfolio company AOA Dx has won TEAMFund Health's 2026 Global Health Innovation Award, which recognizes innovations with the potential to expand access to healthcare globally.
AOA Dx is developing OMIRAâ„¢ OC, a blood test designed to detect ovarian cancer earlier in women who already have symptoms, which are often mistaken for less serious conditions. Because it only needs a blood sample, the test could bring earlier diagnosis to women in places without specialized imaging or diagnostic labs.